195 related articles for article (PubMed ID: 24349109)
1. Expression and functional relevance of cannabinoid receptor 1 in Hodgkin lymphoma.
Benz AH; Renné C; Maronde E; Koch M; Grabiec U; Kallendrusch S; Rengstl B; Newrzela S; Hartmann S; Hansmann ML; Dehghani F
PLoS One; 2013; 8(12):e81675. PubMed ID: 24349109
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Skinnider BF; Elia AJ; Gascoyne RD; Patterson B; Trumper L; Kapp U; Mak TW
Blood; 2002 Jan; 99(2):618-26. PubMed ID: 11781246
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells.
Stanelle J; Döring C; Hansmann ML; Küppers R
Blood; 2010 Nov; 116(20):4202-11. PubMed ID: 20660789
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Skinnider BF; Elia AJ; Gascoyne RD; Trümper LH; von Bonin F; Kapp U; Patterson B; Snow BE; Mak TW
Blood; 2001 Jan; 97(1):250-5. PubMed ID: 11133768
[TBL] [Abstract][Full Text] [Related]
5. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).
Murphy D; Parker J; Zhou M; Fadlelmola FM; Steidl C; Karsan A; Gascoyne RD; Chen H; Banerjee D
Mol Cancer; 2010 Jan; 9():14. PubMed ID: 20100355
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.
Ciaglia E; Torelli G; Pisanti S; Picardi P; D'Alessandro A; Laezza C; Malfitano AM; Fiore D; Pagano Zottola AC; Proto MC; Catapano G; Gazzerro P; Bifulco M
Oncotarget; 2015 Jun; 6(17):15464-81. PubMed ID: 26008966
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid CB
Weresa J; Pędzińska-Betiuk A; Kossakowski R; Malinowska B
Pharmacol Rep; 2019 Feb; 71(1):82-89. PubMed ID: 30500553
[TBL] [Abstract][Full Text] [Related]
8. AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-β - An in vitro study.
Correia-Sá IB; Carvalho CM; Serrão PV; Machado VA; Carvalho SO; Marques M; Vieira-Coelho MA
Eur J Pharmacol; 2021 Feb; 892():173738. PubMed ID: 33220269
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor 1 regulates ERK and GSK-3β-dependent glucocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells.
Wu RW; Lin TP; Ko JY; Yeh DW; Chen MW; Ke HC; Wu SL; Wang FS
Bone; 2011 Dec; 49(6):1255-63. PubMed ID: 21914493
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin lymphoma: Pathology and biology.
Mathas S; Hartmann S; Küppers R
Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
12. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation.
Gustafsson K; Wang X; Severa D; Eriksson M; Kimby E; Merup M; Christensson B; Flygare J; Sander B
Int J Cancer; 2008 Sep; 123(5):1025-33. PubMed ID: 18546271
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.
Nie K; Gomez M; Landgraf P; Garcia JF; Liu Y; Tan LH; Chadburn A; Tuschl T; Knowles DM; Tam W
Am J Pathol; 2008 Jul; 173(1):242-52. PubMed ID: 18583325
[TBL] [Abstract][Full Text] [Related]
14. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
Natoli A; Lüpertz R; Merz C; Müller WW; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2013 Oct; 133(8):1945-54. PubMed ID: 23553437
[TBL] [Abstract][Full Text] [Related]
15. Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.
Zhou M; Fadlelmola FM; Cohn JB; Skinnider B; Gascoyne RD; Banerjee D
Mol Cancer; 2008 Jan; 7():12. PubMed ID: 18218123
[TBL] [Abstract][Full Text] [Related]
16. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
Gibcus JH; Kroesen BJ; Koster R; Halsema N; de Jong D; de Jong S; Poppema S; Kluiver J; Diepstra A; van den Berg A
J Pathol; 2011 Dec; 225(4):609-17. PubMed ID: 21953646
[TBL] [Abstract][Full Text] [Related]
17. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
18. PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis.
Abu-Ghanem S; Oberkovitz G; Benharroch D; Gopas J; Livneh E
Cancer Biol Ther; 2007 Sep; 6(9):1375-80. PubMed ID: 17786031
[TBL] [Abstract][Full Text] [Related]
19. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Schwering I; Bräuninger A; Klein U; Jungnickel B; Tinguely M; Diehl V; Hansmann ML; Dalla-Favera R; Rajewsky K; Küppers R
Blood; 2003 Feb; 101(4):1505-12. PubMed ID: 12393731
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
